DV
Dividend Vision

IRWD — Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. (IRWD)

Total return is -55.8% over the past 16.5 years, 903.0 points behind SPY at 847.2%. Its deepest 1-year drawdown was 43.6%.

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases, with its primary commercial product being linaclotide (marketed as LINZESS and CONSTELLA) for constipation and irritable bowel syndrome, alongside a pipeline of experimental treatments for visceral pain conditions and short bowel syndrome developed through partnerships with major pharmaceutical companies including AbbVie, AstraZeneca, and Astellas Pharma. The company does not currently pay distributions to shareholders. Ironwood appeals to investors seeking exposure to specialized pharmaceutical development rather than current income.

IRWD key facts

Asset type
Stock
Asset class
Equity
Inception date
02/03/2010
Distribution frequency
None
Last close
$4.31
Market cap
$712,184,192
Average volume
2334027.0
Beta
0.21
Payout ratio
0.0
P/E ratio
5.4557
Forward P/E
12.3305
EPS
$0.79